# The First Sertoli Cell Tumor of the Adrenal Gland is Potentially Associated with Arterial Hypertension

## TL;DR

This paper reports the first case of a Sertoli cell tumor in the adrenal gland, which was linked to the patient's hypertension and successfully treated with surgery.

## Contribution

The novelty lies in the first documented case of a primary Sertoli cell tumor in the adrenal gland.

## Key findings

- A 44-year-old male with hypertension was diagnosed with a Sertoli cell tumor in the adrenal gland.
- Laparoscopic adrenalectomy successfully removed the tumor, and the patient's hypertension resolved post-surgery.
- The tumor showed specific immunohistochemical markers and no recurrence was observed during 15 months of follow-up.

## Abstract

Sertoli cell tumors are rare sex cord-stromal tumors, accounting for less than 1% of primary testicular tumors. They typically arise in the testes and ovaries, with other localizations being uncommon. We present the case of a Sertoli cell tumor in the adrenal gland, which, to our knowledge, is the first reported in the literature.

A 44-year-old male patient was admitted to the clinic for endocrine surgery for laparoscopic surgery of a right adrenal gland incidentaloma measuring 57 × 47 × 59 mm, discovered during a routine abdominal ultrasonography. The patient had a history of hypertension but no other comorbidities. Biochemical and physical examinations revealed no signs of hypercortisolism. Urinary metanephrine and normetanephrine levels were within normal limits. A right laparoscopic adrenalectomy was performed, and a 5 cm tumor was identified without evidence of locoregional invasion. Pathological examination confirmed a Sertoli cell tumor of the adrenal gland. Immunohistochemical analysis revealed positive staining for vimentin, steroidogenic factor 1 (SF1), and beta-catenin, while chromogranin A, hCG, PSA, and TTF1 were negative. The Ki-67 index was 3%. The patient was subsequently referred to a urologist, where testicular ultrasonography showed no abnormalities. There were no signs of recurrence during a 15-month follow-up period. Additionally, the patient’s biannual antihypertensive treatment was discontinued by a cardiologist 1.5 months post-surgery.

Sertoli cell tumors are an exceptionally rare entity. To our knowledge, this is the first reported case of a primary Sertoli cell tumor originating in the adrenal gland. Given their potential for malignancy, regular follow-up and additional diagnostic evaluations may be necessary. Laparoscopic adrenalectomy appears to be a suitable definitive treatment for this condition.